A 62-year-old man from Mumbai with a history of hypertension (on amlodipine) presents with nocturia 3 times per night and mild hesitancy for 6 months. Digital rectal examination shows a smooth, firm prostate estimated at 25–30 g. Post-void residual is 45 mL. IPSS is 14 (mild-to-moderate). Uroflowmetry shows peak flow of 14 mL/s. PSA is 1.9 ng/mL. He is keen for treatment. Which is the most appropriate initial management?

Explanation

## Clinical Context **Key Point:** This patient has mild-to-moderate symptomatic BPH with minimal obstruction (peak flow 14 mL/s is near-normal, PVR 45 mL is acceptable, IPSS 14 is mild-to-moderate) and a small-to-moderate prostate gland. ## BPH Management Hierarchy ```mermaid flowchart TD A[Symptomatic BPH]:::outcome --> B{Severity of symptoms?}:::decision B -->|Mild IPSS < 8| C[Watchful waiting / lifestyle]:::action B -->|Mild-moderate IPSS 8-19| D[Medical therapy: alpha-blocker]:::action B -->|Moderate-severe IPSS ≥ 20| E{Obstruction confirmed?}:::decision E -->|Yes| F[Consider surgery]:::action E -->|No| G[Optimize medical therapy]:::action D --> H[Reassess at 4-6 weeks]:::outcome ``` ## Why Alpha-Blocker Monotherapy Is First-Line | Parameter | Finding | Interpretation | |-----------|---------|----------------| | **IPSS** | 14 | Mild-to-moderate (not severe) | | **Peak flow** | 14 mL/s | Minimal obstruction (normal >15 mL/s) | | **PVR** | 45 mL | Acceptable (not significant) | | **Prostate size** | 25–30 g | Small-to-moderate | | **Symptom duration** | 6 months | Established but not severe | **High-Yield:** Alpha-blockers (tamsulosin, alfuzosin, doxazosin) are first-line medical therapy for symptomatic BPH because they provide rapid symptom relief (within 1–2 weeks) by relaxing smooth muscle in the prostate and bladder neck. They are indicated for IPSS 8–19 without severe obstruction [cite:Wein et al. Campbell-Walsh Urology 12e Ch 107]. ## Why Other Options Are Premature or Incorrect **TURP:** Surgical intervention is reserved for severe symptoms (IPSS ≥20) with confirmed obstruction, failure of medical therapy, or complications (recurrent UTI, hematuria, renal insufficiency). This patient has mild-to-moderate symptoms and minimal obstruction. **Combination therapy (alpha-blocker + 5-alpha reductase inhibitor):** Indicated when: - Prostate gland is large (>40 g), OR - PSA is elevated (>1.5 ng/mL) suggesting significant adenoma, OR - Monotherapy has failed after 4–6 weeks. This patient has a small-to-moderate gland and low PSA; monotherapy is appropriate first-line. **TUIP:** Surgical procedure for small glands (<30 g) with minimal obstruction. Even if surgery were indicated, TUIP would be considered only after failed medical therapy, which has not been attempted here. ## Clinical Pearl **Key Point:** The combination of mild-to-moderate IPSS, normal peak flow (14 mL/s), and low PVR (45 mL) indicates that this patient will respond well to medical therapy. Surgery is not indicated at this stage. **Mnemonic:** **SOAP** — Start with alpha-blocker, Observe for 4–6 weeks, Add 5-alpha reductase inhibitor if large prostate or PSA >1.5, Proceed to surgery if medical therapy fails.